Non-hormonal hot flash treatment: what actually works

Hot flashes — clinically called vasomotor symptoms (VMS) — are the most common symptom of the menopause transition. Hormone therapy is the most effective treatment, but it is not the right choice for everyone. Women with a history of hormone-sensitive breast cancer, blood clots, or stroke may have contraindications, and others simply prefer to avoid hormones. The good news: evidence-based non-hormonal options are better than they have ever been.

FDA-approved non-hormonal medications

Three non-hormonal medications are FDA-approved for moderate-to-severe hot flashes due to menopause. Low-dose paroxetine (Brisdelle, 7.5 mg) is an SSRI that modulates the brain chemistry involved in temperature regulation. Other SSRIs and SNRIs such as venlafaxine are also commonly used off-label with strong support from NAMS and ACOG.

In 2023, the FDA approved fezolinetant (Veozah) — a first-in-class neurokinin B (NKB) receptor antagonist. As estrogen falls during menopause, NKB activity rises and disrupts the brain's thermostat. Fezolinetant blocks that pathway directly and meaningfully reduces both the frequency and severity of moderate-to-severe hot flashes.

In October 2025, the FDA approved elinzanetant (Lynkuet), which blocks both neurokinin-1 and neurokinin-3 receptors, for moderate-to-severe hot flashes due to menopause. Lynkuet has no boxed warning; its label warnings include central nervous system depressant effects and daytime impairment (such as sleepiness), liver enzyme (hepatic transaminase) elevations that require liver blood tests before starting and at 3 months, risk of pregnancy loss, and risk of seizure. Fezolinetant (Veozah) carries a boxed warning for risk of liver injury (hepatotoxicity): liver blood tests are required before starting, monthly for the first 3 months, and at 6 and 9 months, and it should be stopped right away if signs of liver injury appear. Review side effects and suitability with a clinician.

Off-label prescription options

• Gabapentin — originally for seizures and nerve pain, reduces hot flash frequency by roughly 50% in trials; often taken at bedtime since drowsiness can help night sweats
• Clonidine — a blood pressure medication with modest VMS effect, available as a daily pill or weekly patch; side effects include dizziness and dry mouth
• Oxybutynin — used at low dose for VMS in some patients, particularly when sweating is the dominant complaint

Mind-body approaches with real evidence

The 2023 NAMS Nonhormone Therapy Position Statement specifically endorses cognitive behavioral therapy (CBT) and clinical hypnosis for hot flashes. CBT does not necessarily reduce the number of hot flashes but reliably reduces how bothersome they feel — which is what most women actually care about. Clinical hypnosis, performed by a trained clinician, has been shown in multiple trials to reduce both frequency and severity.

Lifestyle adjustments that move the needle

• Identify and avoid personal triggers — most commonly alcohol, caffeine, spicy food, and acute stress
• Dress in breathable layers; keep a fan at your desk and bedside
• Aim for a healthy weight — higher BMI is associated with more frequent and severe hot flashes
• Protect sleep aggressively; sleep loss amplifies VMS in every study

A note on supplements

Black cohosh, soy isoflavones, red clover, and dong quai are widely marketed for menopause relief, but the evidence is weak, mixed, or inconclusive. Supplements are not FDA-regulated the way prescription drugs are, so purity and potency are not guaranteed, and several can interact with other medications. Always discuss any supplement with your clinician before starting.

The bottom line

You have more proven non-hormonal hot flash options than ever before — and you do not have to simply power through. The right choice depends on your medical history, symptom severity, and personal preferences. A clinician trained in menopause medicine can help you build a personalized plan.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: May 10, 2026